Epstein-Barr virus latent membrane protein 2-derived peptide-MHC class I complex (EBV LMP2-pMHC I) (EBV LMP2-pMHC I)

Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2)-derived peptide epitopes presented on MHC class I molecules are key targets for immunotherapy in EBV-associated malignancies. LMP2 is a transmembrane protein expressed during EBV latency types II and III, which are characteristic of nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, and NK/T-cell lymphomas (PMID: 30633419). These peptides, such as the HLA-A*02:01-restricted CLGGLLTMV epitope, are processed intracellularly and presented on the cell surface, allowing the immune system to identify infected or transformed cells (PMID: 25108615). Because LMP2 is a viral protein, its epitopes are distinct from human self-antigens, reducing the risk of central tolerance and making them ideal for T-cell receptor (TCR) based therapies. Current clinical approaches include the use of EBV-specific cytotoxic T-lymphocytes (CTLs), TCR-engineered T-cells, and therapeutic vaccines designed to elicit a robust CD8+ T-cell response (PMID: 33806305). These therapies rely on the high-affinity binding of the TCR to the specific peptide-HLA complex to trigger cell death. However, challenges such as HLA downregulation by tumor cells and the immunosuppressive tumor microenvironment remain significant hurdles for efficacy. Additionally, the diversity of HLA alleles across populations requires the development of multiple TCRs to cover a broad patient base.

Other names

LMP2-HLA complexEBV LMP2 peptide-HLA complexLatent membrane protein 2 epitopeEBV LMP2A/B-derived MHC I complex

Targeted T-cell mediated cytotoxicity via T-cell receptor (TCR) recognition of the peptide-MHC complex (PMID: 33806305).